-
公开(公告)号：US20180185546A1
公开(公告)日：2018-07-05
申请号：US15909857
申请日：2018-03-01
申请人： Amnio Technology LLC
CPC分类号： A61K35/50 , A61K31/728 , A61K35/35 , A61L27/3604 , A61L27/3683
摘要： An enriched amnion derived tissue graft has a stromal matrix layer and an epithelium layer. A stromal matrix layer may contain a basement membrane layer, a compact layer, a fibroblast layer, and an intermediate layer. An amnion derived tissue graft may have a plurality of tissue layers and the layers may be configured with the epithelium layers toward the inside and the stromal matrix layers toward the outside surface. An enriched portion may be coated onto or be configured within a tissue layer and have an increased concentration of cells, of proteins, growth factors, seed cells, pharmaceuticals or any combination thereof. A carrier fluid such as amniotic fluid may be used to produce an enrichment composition for coating the tissue graft. The cells within the enriched portion may be stem cells from the amnion, or cells from other tissue and may be seed cells selected based on the treatment location.
-
公开(公告)号：US09132156B1
公开(公告)日：2015-09-15
申请号：US14593415
申请日：2015-01-09
申请人： Amnio Technology LLC
CPC分类号： A61K35/50 , A61K8/982 , A61K35/28 , A61K35/35 , A61K35/44 , A61M2037/0061 , A61Q19/08 , A61K2300/00
摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic stems cells. The amniotic stem cells may be destroyed, and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized amniotic membrane particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
摘要翻译： 描述了具有许多各种组成实施方案的无细胞羊膜衍生治疗组合物。 无细胞羊膜衍生的治疗组合物基本上没有活的或活跃的羊膜干细胞。 羊膜干细胞可能被破坏，并且细胞和细胞碎片可以从无细胞羊膜来源的治疗组合物中去除。 无细胞羊膜衍生的治疗组合物可以包含微粉化的羊膜膜颗粒和/或羊水。 脱细胞羊膜衍生治疗组合物可以是与流体如血浆，盐水，羊水，其组合等组合的微粉化羊膜的分散体。 可将无细胞羊膜衍生的治疗组合物与基质组分组合以形成复合物。 来自非细胞羊膜的治疗组合物可以与包含活细胞如干细胞的组合物结合使用。
-
公开(公告)号：US12011465B1
公开(公告)日：2024-06-18
申请号：US17879746
申请日：2022-08-02
申请人： Amnio Technology LLC
发明人： Robert B. Diller , Sarah Berglund
IPC分类号： A61K35/50 , A61K9/00 , A61K9/50 , A61K31/728 , A61K47/20
CPC分类号： A61K35/50 , A61K9/0024 , A61K9/5084 , A61K31/728 , A61K47/20
摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
-
公开(公告)号：US20220055155A1
公开(公告)日：2022-02-24
申请号：US17515964
申请日：2021-11-01
申请人： Amnio Technology LLC
发明人： Merrill Stromer , Larry Macal , Donald R. Taylor , Cris Holmes , James E. Ellis
IPC分类号： B23K26/38 , A61L27/36 , B23K26/402 , B25J11/00 , B25J9/16 , B25J13/08 , B23K37/04 , B23K26/082
摘要： An allograft optimization system utilizes an optical system to determine the outer perimeter of a tissue blank for allograft cutting therefrom. The optical system determines an optimal allograft array pattern that can be derived from the irregular tissue blank and may include a plurality of various allograft shapes and sizes. A computer operates an allograft optimization computer program that receives input regarding the outer perimeter of the tissue blank. A cutting implement, such as a laser, is configured to cut the allografts from the irregularly shaped tissue blank according the allograft array pattern. The cutting implement is automatically actuated by an actuator with respect to the tissue blank to cut the allografts therefrom. The cutting implement may be a laser or a galvo laser that is directed by one or more mirrors. The tissue may be birth tissue including placental tissue and amnion.
-
公开(公告)号：US11161204B1
公开(公告)日：2021-11-02
申请号：US16951790
申请日：2020-11-18
申请人： Amnio Technology LLC
发明人： Merrill Stromer , Larry Macal , Donald R. Taylor , Cris Holmes , James E. Ellis
IPC分类号： B23K26/38 , A61L27/36 , B23K26/402 , B25J11/00 , B25J9/16 , B25J13/08 , B23K37/04 , B23K26/082 , B25J9/02
摘要： An allograft optimization system utilizes an optical system to determine the outer perimeter of a tissue blank for allograft cutting therefrom. The optical system determines an optimal allograft array pattern that can be derived from the irregular tissue blank and may include a plurality of various allograft shapes and sizes. A computer operates an allograft optimization computer program that receives input regarding the outer perimeter of the tissue blank. A cutting implement, such as a laser, is configured to cut the allografts from the irregularly shaped tissue blank according the allograft array pattern. The cutting implement is automatically actuated by an actuator with respect to the tissue blank to cut the allografts therefrom. The cutting implement may be a laser or a galvo laser that is directed by one or more mirrors. The tissue may be birth tissue including placental tissue and amnion.
-
公开(公告)号：US20210316399A1
公开(公告)日：2021-10-14
申请号：US16951790
申请日：2020-11-18
申请人： Amnio Technology LLC
发明人： Merrill Stromer , Larry Macal , Donald R. Taylor , Cris Holmes , James E. Ellis
IPC分类号： B23K26/38 , A61L27/36 , B23K26/402 , B25J11/00 , B25J9/16 , B25J13/08 , B23K37/04 , B23K26/082
摘要： An allograft optimization system utilizes an optical system to determine the outer perimeter of a tissue blank for allograft cutting therefrom. The optical system determines an optimal allograft array pattern that can be derived from the irregular tissue blank and may include a plurality of various allograft shapes and sizes. A computer operates an allograft optimization computer program that receives input regarding the outer perimeter of the tissue blank. A cutting implement, such as a laser, is configured to cut the allografts from the irregularly shaped tissue blank according the allograft array pattern. The cutting implement is automatically actuated by an actuator with respect to the tissue blank to cut the allografts therefrom. The cutting implement may be a laser or a galvo laser that is directed by one or more mirrors. The tissue may be birth tissue including placental tissue and amnion.
-
公开(公告)号：US10894066B2
公开(公告)日：2021-01-19
申请号：US15257870
申请日：2016-09-06
申请人： Amnio Technology LLC
IPC分类号： A61K35/50
摘要： Therapeutic compositions are described for the treatment of a variety of conditions including heart, eye, lungs, organs, joints, dermal, nerve, and the like. A therapeutic composition may be a fluid comprising amniotic fluid or micronized amniotic particles. A therapeutic composite may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. In another embodiment, the therapeutic composite is a mixture of micronized amniotic membrane particles combined with an amniotic rich stem cell fluid. An amniotic rich or concentrated stem cell fluid comprises at least 0.5×106 amniotic stem cells per milliliter of fluid or composition. A therapeutic composite may be used to treat any number of conditions through topical application, surgical introduction, and/or injection.
-
公开(公告)号：US09814746B2
公开(公告)日：2017-11-14
申请号：US14853889
申请日：2015-09-14
申请人： Amnio Technology LLC
IPC分类号： A61K35/50 , A61K9/00 , A61K9/06 , A61Q19/00 , A61Q19/08 , A61K8/98 , A61K35/28 , A61K35/35 , A61K35/44
CPC分类号： A61K35/50 , A61K8/982 , A61K9/0014 , A61K9/0019 , A61K9/0034 , A61K9/0046 , A61K9/0048 , A61K9/0053 , A61K9/06 , A61K35/28 , A61K35/35 , A61K35/44 , A61K2800/74 , A61Q19/00 , A61Q19/08 , A61K2300/00
摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed, and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
-
公开(公告)号：US20160375064A1
公开(公告)日：2016-12-29
申请号：US15257870
申请日：2016-09-06
申请人： Amnio Technology LLC
CPC分类号： A61K35/50 , A61K8/982 , A61Q19/08 , A61K2300/00
摘要： Therapeutic compositions are described for the treatment of a variety of conditions including heart, eye, lungs, organs, joints, dermal, nerve, and the like. s, A therapeutic composition may be a fluid comprising amniotic fluid or micronized amniotic particles. A therapeutic composite may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. In another embodiment, the therapeutic composite is a mixture of micronized amniotic membrane particles combined with an amniotic rich stem cell fluid. An amniotic rich or concentrated stem cell fluid comprises at least 0.5×106 amniotic stem cells per milliliter of fluid or composition. A therapeutic composite may be used to treat any number of conditions through topical application, surgical introduction, and/or injection.
摘要翻译： 描述了治疗组合物用于治疗各种病症，包括心脏，眼睛，肺，器官，关节，皮肤，神经等。 治疗组合物可以是包含羊水或微粉化羊膜颗粒的流体。 治疗性复合物可以是与流体如血浆，盐水，羊水，其组合等组合的微粉化羊膜的分散体。 在另一个实施方案中，治疗性复合物是与富含羊水的干细胞流体组合的微粉化羊膜膜颗粒的混合物。 富含羊水或浓缩的干细胞流体含有每毫升流体或组合物至少0.5×10 6个羊水干细胞。 治疗性复合物可用于通过局部施用，手术引入和/或注射来治疗任何数量的病症。
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.02 秒)
